

# Gilead Sciences, Inc.- Company Snapshot & SWOT Analysis

<https://marketpublishers.com/r/G6AFEE4CE08EN.html>

Date: March 2019

Pages: 30

Price: US\$ 200.00 (Single User License)

ID: G6AFEE4CE08EN

## Abstracts

Gilead Sciences, Inc. (Gilead) is a U.S. based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. Gilead's primary areas of focus include HIV/AIDS, liver diseases, hematology/oncology and inflammation/respiratory diseases.

Gilead Sciences registered profit in the fourth quarter from a loss last year, helped by a push in income taxes provision.

Company's 2018 Revenue declined 2.6% to USD 5.8 billion. The results reflected by lower product sales in Europe and in other regions. Chronic hepatitis C virus franchise sales plunged 50.8% due to lower average selling price and lower sales volume of Harvoni and Epclusa across all major markets as a result of increased generic competition and the lower patient engagement.

For the fourth quarter, R&D expenses increased by 69.6% Y-O-Y. This was primarily due to an impairment charge related to in-process R&D for multiple myeloma treating program, up-front collaboration expenses and higher investments to support the growth of Gilead's business following the acquisition of Kite.

Spanning over 30 pages and 18 exhibits, "Gilead Sciences, Inc. - Company Snapshot & SWOT Analysis" report provides value chain analysis, financial performance, business strategy and SWOT analysis for company.

Scope of the Gilead Sciences, Inc.- Company Snapshot & SWOT Analysis Report

This report provides detailed information about Gilead Sciences, Inc. including

value chain analysis, financial performance, business strategy and SWOT analysis.

The report identifies the growth drivers and inhibitors for global pharmaceutical market.

This report provides information about current and future trends for global pharmaceutical market.

## Contents

### **1. EXECUTIVE SUMMARY**

Scope of the Gilead Sciences, Inc.- Company Snapshot & SWOT Analysis Report  
Research Methodology

### **2. GROWTH DRIVERS AND INHIBITORS FOR GLOBAL PHARMACEUTICALS MARKET**

### **3. COMPANY PROFILE**

#### 3.1 Gilead Sciences Inc.

##### 3.1.1. Company Profile

##### 3.1.2 Gilead Sciences, Inc. in Global Pharmaceuticals Manufacturing Value Chain

##### 3.1.3 Gilead Sciences, Inc.: Financial Performance

##### 3.1.4 Gilead Sciences, Inc.: Geography wise Performance

##### 3.1.5 Gilead Sciences, Inc.: Business Strategy

##### 3.1.5.1 Gilead Sciences, Inc. Revenue by Business Segment

##### 3.1.6 SWOT Analysis of Gilead Sciences, Inc.

Strengths

Weaknesses

Opportunities

Threats

### **4. CURRENT AND FUTURE TRENDS IN PHARMACEUTICAL MARKET**

Orphan Drugs

Biologics and Biosimilars

Current Trends

Company Information

## List Of Exhibits

### LIST OF EXHIBITS

- Exhibit 2.1 Growth Drivers and Inhibitors for Global Pharmaceuticals Market
- Exhibit 3.1 Key Information of Gilead Sciences, Inc.
- Exhibit 3.2 Contact Information of Gilead Sciences, Inc.
- Exhibit 3.3 Gilead Sciences, Inc. in Global Pharmaceuticals Manufacturing Value Chain
- Exhibit 3.4 Gilead Sciences, Inc. Revenue 2014-2019 (in USD billion)
- Exhibit 3.5 Year-wise Gilead Sciences, Inc. Revenue Growth 2014-19 (in %)
- Exhibit 3.6 Gilead Sciences, Inc. Geography Wise Revenue Share in (%) 2018
- Exhibit 3.7 Gilead Sciences, Inc. Geography Wise Revenue in USD Billion (2016 - 2018)
- Exhibit 3.8 Gilead Sciences, Inc. Business Segment Revenue Share 2018
- Exhibit 3.9 Gilead Sciences, Inc. Segment wise Revenue in USD Billion (2016- 2018)
- Exhibit 3.10 Gilead Sciences, Inc. Revenue from HIV Product Sales (2016-2018)
- Exhibit 3.11 Gilead Sciences, Inc. HIV Product Sales by Medicine in USD Million (2018)
- Exhibit 3.12 Gilead Sciences, Inc. Revenue from HCV Product Sales (2016-2018)
- Exhibit 3.13 Gilead Sciences, Inc. HCV Product Sales by Medicine in USD Million (2018)
- Exhibit 3.14 Gilead Sciences, Inc. Revenue from HBV, Cardio, Oncology and Others Product Sales (2016-2018)
- Exhibit 3.15 Gilead Sciences, Inc. Revenue from HBV, Cardio, Oncology and Others Product Sales by Medicine in USD Million (2018)
- Exhibit 3.16 Gilead Sciences, Inc. Revenue from Yescarta® Sales (2017-2018)
- Exhibit 3.17 SWOT Analysis of Gilead Sciences, Inc.

## I would like to order

Product name: Gilead Sciences, Inc.- Company Snapshot & SWOT Analysis

Product link: <https://marketpublishers.com/r/G6AFEE4CE08EN.html>

Price: US\$ 200.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G6AFEE4CE08EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970